IN2015DN03796A - - Google Patents

Info

Publication number
IN2015DN03796A
IN2015DN03796A IN3796DEN2015A IN2015DN03796A IN 2015DN03796 A IN2015DN03796 A IN 2015DN03796A IN 3796DEN2015 A IN3796DEN2015 A IN 3796DEN2015A IN 2015DN03796 A IN2015DN03796 A IN 2015DN03796A
Authority
IN
India
Prior art keywords
gene signatures
autoimmune disorders
metabolic
inflammation
disorders
Prior art date
Application number
Inventor
Matthieu Pichaud
Pierre Rimbaud
Stanislav Ehrlich
Original Assignee
Enterome
Agronomique Inst Nat Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome, Agronomique Inst Nat Rech filed Critical Enterome
Publication of IN2015DN03796A publication Critical patent/IN2015DN03796A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

This invention is related to the area of characterization of inflammation in relation with the gut microbiota in metabolic and autoimmune disorders. In particular it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases such as liver related metabolic disorders in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis prognosis stratification for drug studies for monitoring patient and for assigning an appropriate treatment.
IN3796DEN2015 2012-10-17 2013-10-17 IN2015DN03796A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306286 2012-10-17
PCT/EP2013/071793 WO2014060555A1 (en) 2012-10-17 2013-10-17 Gene signatures of inflammatory disorders that relate to the liver

Publications (1)

Publication Number Publication Date
IN2015DN03796A true IN2015DN03796A (en) 2015-10-02

Family

ID=47148686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3796DEN2015 IN2015DN03796A (en) 2012-10-17 2013-10-17

Country Status (14)

Country Link
US (2) US10036074B2 (en)
EP (1) EP2909334B1 (en)
JP (2) JP6752016B2 (en)
CN (1) CN104769132B (en)
AU (2) AU2013333882B2 (en)
BR (1) BR112015008621A2 (en)
CA (1) CA2886748A1 (en)
DK (1) DK2909334T3 (en)
ES (1) ES2821383T3 (en)
IL (1) IL238025B (en)
IN (1) IN2015DN03796A (en)
MX (1) MX2015004844A (en)
NZ (1) NZ707035A (en)
WO (1) WO2014060555A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CA3016059A1 (en) 2016-03-04 2017-09-08 The Regents Of The University Of California Microbial consortium and uses thereof
EP3445871A1 (en) * 2016-04-20 2019-02-27 Human Longevity, Inc. Use of a microbiome profile to detect liver disease
ES2871060T3 (en) * 2016-05-11 2021-10-28 Univ Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for autoimmune / inflammatory digestive diseases
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
CN107271674B (en) * 2017-06-13 2019-05-07 首都医科大学附属北京地坛医院 A kind of target marker GP73 and detection application method for steatohepatitis detection
WO2019199895A1 (en) 2018-04-10 2019-10-17 Siolta Therapeutics, Inc. Microbial consortia
CN108504739A (en) * 2018-05-15 2018-09-07 浙江大学 A kind of biomarker and its application for hepatocarcinoma early diagnosis
EP3899015A1 (en) * 2018-12-19 2021-10-27 Astrazeneca AB Biomarker of pnpla3 expression
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
WO2021071864A1 (en) 2019-10-07 2021-04-15 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
CN111884792B (en) * 2020-06-30 2021-07-09 深圳市永达电子信息股份有限公司 System and method for preparing eigen-state network circuit signal based on memristor chaotic sequence
US11688507B2 (en) 2020-12-29 2023-06-27 Kpn Innovations, Llc. Systems and methods for generating a metabolic dysfunction nourishment program

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
KR20020097200A (en) * 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 Identification of essential genes in prokaryotes
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
ES2405405T3 (en) * 2001-12-17 2013-05-31 Corixa Corporation Compositions and procedures for the therapy and diagnosis of inflammatory bowel disease
US8119365B2 (en) * 2002-01-23 2012-02-21 Wisconsin Alumni Research Foundation Insertion sequence-free bacteria
JPWO2004092365A1 (en) * 2003-04-13 2006-07-06 株式会社産学連携機構九州 Extraction and selection method for hepatic disorder-related genes and evaluation and diagnosis of liver disorder or liver function using the same
US7860656B2 (en) * 2005-02-03 2010-12-28 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of hepatic steatosis using biochemical markers
WO2006089264A2 (en) * 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
FR2893136A1 (en) * 2005-11-10 2007-05-11 Sanofi Aventis Sa METHODS OF DIAGNOSING HEPATIC DISEASES AND SCREENING MOLECULES FOR THE TREATMENT OF THESE DISEASES
US20110165568A1 (en) * 2009-12-31 2011-07-07 Life Technologies Corporation Sequences of e.coli 055:h7 genome
US20130045874A1 (en) * 2010-03-01 2013-02-21 Institut National De La Recherche Agronomique Method of Diagnostic of Inflammatory Bowel Diseases
JP5757032B2 (en) * 2010-04-05 2015-07-29 学校法人東京医科大学 Method for testing fibrosis of chronic liver disease using miRNA
JP2012125215A (en) * 2010-12-17 2012-07-05 Osaka City Univ Method for determining presence and/or severity of hepatic fibrosis, determining marker and kit used for determination, and method for predicting therapeutic effect of hepatic fibrosis, effect prediction marker, and kit used for effect prediction
WO2012105590A1 (en) * 2011-02-01 2012-08-09 アステラス製薬株式会社 Determination marker for non-alcoholic steatohepatitis, and method for diagnosing non-alcoholic steatohepatitis using the marker as measure
WO2012159023A2 (en) * 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
EP2763540A4 (en) * 2011-09-09 2015-04-22 Univ Yale Compositions and methods for assessing and treating inflammatory diseases and disorders
US20140377278A1 (en) * 2012-01-10 2014-12-25 Yale University Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders
WO2014060538A1 (en) 2012-10-17 2014-04-24 Institut National De La Recherche Agronomique Determination of reduced gut bacterial diversity
WO2014060537A1 (en) 2012-10-17 2014-04-24 Institut National De La Recherche Agronomique Prognostic of diet impact on obesity-related co-morbidities
US20150284779A1 (en) 2012-10-17 2015-10-08 Institut National De La Recherche Agronomique Determination of a tendency to gain weight
US9459650B2 (en) 2014-03-17 2016-10-04 Qualcomm Incorporated Clock pulse generator for multi-phase signaling

Also Published As

Publication number Publication date
IL238025B (en) 2020-05-31
JP6752016B2 (en) 2020-09-09
BR112015008621A2 (en) 2018-08-28
CA2886748A1 (en) 2014-04-24
US20180251819A1 (en) 2018-09-06
CN104769132A (en) 2015-07-08
US10036074B2 (en) 2018-07-31
AU2013333882B2 (en) 2019-05-16
MX2015004844A (en) 2015-11-16
AU2013333882A1 (en) 2015-05-07
EP2909334A1 (en) 2015-08-26
ES2821383T3 (en) 2021-04-26
JP2015535177A (en) 2015-12-10
US10626471B2 (en) 2020-04-21
CN104769132B (en) 2018-05-08
US20160068890A1 (en) 2016-03-10
JP2019092522A (en) 2019-06-20
IL238025A0 (en) 2015-05-31
EP2909334B1 (en) 2020-06-24
WO2014060555A1 (en) 2014-04-24
NZ707035A (en) 2018-11-30
AU2019210666A1 (en) 2019-08-22
DK2909334T3 (en) 2020-09-28

Similar Documents

Publication Publication Date Title
IN2015DN03796A (en)
CA2941917C (en) Methods for the diagnosis and treatment of inflammatory bowel disease
MX2016002879A (en) Systems, devices and methods for anti-tl1a therapy.
MA39963A (en) Methods for treating inflammatory bowel disease
NZ602704A (en) Method of diagnostic of inflammatory bowel diseases
MX2015015784A (en) Methods for diagnosing and treating inflammatory bowel disease.
MX2017015210A (en) Compositions and methods for screening solid tumors.
PH12016502167A1 (en) Hdl theraphy markers
MX2022012384A (en) Compositions and methods for screening mutations in thyroid cancer.
UA115540C2 (en) Anti il-36r antibodies
IN2014MN01642A (en)
MX2022010809A (en) Methods for diagnosing and treating inflammatory bowel disease.
MX2017015700A (en) Igfbp3 and uses thereof.
HK1159659A1 (en) Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) -i( i)
BR112017014107A2 (en) nutritional composition useful in treating patients with ibd
MA39710A (en) Topical composition for use in the treatment of inflammatory bowel disease
MX344543B (en) Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders.
WO2015132670A3 (en) Methods and compositions for detection of targets for autoimmune disease
EP3052661A4 (en) Methods for assessing status of post-transplant liver and determining and administering specific treatment regimens
MX2022008842A (en) Proteins for the treatment of epithelial barrier function disorders.
EP2852570A4 (en) Compositions and methods for the treatment of inflammatory bowel disease
MA40592A (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
HRP20190211T1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
MX2017006959A (en) Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease.
IN2014DN06662A (en)